{"entity":{"id":"exopert-emerald","kind":"trial","name":"EMERALD (EXoPERT extracellular vesicle Raman test)","aka":["EXoPERT EMERALD","EXoPred"],"tldr":"A US study collecting blood to develop an artificial intelligence test that reads light scattered by tiny vesicles shed from tumours.","summary":"EMERALD (NCT07186296) is an observational study sponsored by EXoPERT with MCRA. It builds a repository to develop artificial intelligence software that analyses surface-enhanced Raman spectroscopy profiles of plasma extracellular vesicles for early detection of five cancers.\n\nThe registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,400 participants, a start on 9 May 2025 and primary completion expected on 31 August 2026.","status":"recruiting","asOf":"2026-10-29","links":[{"label":"ClinicalTrials.gov NCT07186296","url":"https://clinicaltrials.gov/study/NCT07186296"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07186296","phase":"observational","setting":"People with lung, ovarian, breast, pancreatic or colorectal cancer and controls at US sites, building a blood sample repository","sponsor":"EXoPERT with MCRA","started":"2025-05-09","startedType":"actual","enrolled":1400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/exopert-emerald/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}]}}